Compare AOSL & PHAR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AOSL | PHAR |
|---|---|---|
| Founded | 2000 | 1988 |
| Country | United States | Netherlands |
| Employees | N/A | N/A |
| Industry | Semiconductors | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.3B | 1.2B |
| IPO Year | 2007 | 2020 |
| Metric | AOSL | PHAR |
|---|---|---|
| Price | $37.25 | $11.94 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 3 |
| Target Price | $24.00 | ★ $38.33 |
| AVG Volume (30 Days) | ★ 1.1M | 8.7K |
| Earning Date | 05-06-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $342,291,000.00 | N/A |
| Revenue This Year | N/A | $10.04 |
| Revenue Next Year | $6.41 | $2.51 |
| P/E Ratio | ★ N/A | $3,041.22 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $17.01 | $8.69 |
| 52 Week High | $49.97 | $21.34 |
| Indicator | AOSL | PHAR |
|---|---|---|
| Relative Strength Index (RSI) | 51.46 | 20.60 |
| Support Level | $26.82 | $11.02 |
| Resistance Level | $45.97 | $17.70 |
| Average True Range (ATR) | 4.47 | 0.37 |
| MACD | -0.26 | -0.37 |
| Stochastic Oscillator | 15.84 | 3.49 |
Alpha & Omega Semiconductor Ltd designs, develops and supplies a portfolio of power semiconductors targeting various applications, including personal computers, flat-panel TVs, LED lighting, smartphones, battery packs, consumer and industrial motor controls and power supplies for TVs, computers, servers and telecommunications equipment. It generates revenue mainly from the sale of power semiconductors, consisting of power discretes and power ICs with a presence in Hong Kong, China, South Korea, the United States and other countries. It operates in one operating segment: the design, development and supply of power semiconductor products for computing, consumer electronics, communication and industrial applications.
Pharming Group is a biotechnology company focused on developing and commercializing therapies for rare and ultra-rare diseases, particularly immunological and genetic conditions with high unmet need. It operates as an integrated company with capabilities across clinical development, manufacturing, regulatory affairs, and commercialization, supported by scientific and operational expertise. It leverages its efficient infrastructure to expand its pipeline and improve patient access to treatment. The Company operates in the United States, Europe, and the rest of the world, with the United States contributing the majority of its revenue.